MedinCell (MEDCL) Jefferies Global Healthcare Conference 2025 summary

Technology and innovation

• Proprietary BEPO technology enables subcutaneous, ready-to-use long-acting injectables with immediate onset, setting new standards in the field.

• BepoStar, the next-generation platform, uses star-shaped PEG to improve formulation features and extends patent life to 2040.

Commercial performance and product pipeline

• UZEDY, a schizophrenia drug, achieved $120M in 2024 sales, surpassing guidance, with 2025 outlook at $160M and rapid prescription growth.

• UZEDY is eligible for $105M in commercial milestones and mid to high single-digit royalties.

• Supplemental NDA for UZEDY in bipolar disorder accepted, with potential label expansion expected by year-end.

• Olanzapine LAI (MDC-TJK) is seen as a $2B+ opportunity, targeting severe schizophrenia with no appropriate competition and potential for a less restrictive label.

• NDA filing for olanzapine LAI is planned for 2H 2024, with European launch also targeted.

Clinical development and partnerships

• MDC-CWM, a long-acting celecoxib for post-knee replacement pain, showed efficacy in patients without prior knee surgery; a new phase 3 study will start by year-end.

• AbbVie partnership covers six programs, with $35M upfront, up to $1.9B in milestones, and mid-single to low double-digit royalties.

• Lead formulation for the first AbbVie program identified; IND filing expected within 18–24 months from last August/September.

• The AbbVie deal has increased visibility and led to more discussions with other pharma companies.